We assessed levels of LINC-PINT, a non-coding RNA (ncRNA), for differential expression between neuropathological AD cases and controls across seven brain regions in a total of 1,186 samples from 800 individuals profiled as part of the AMP-AD consortium (Additional file 1: Table S12) [1, 16, 27, 56]. This evidence concerns the gene LINC-PINT and Alzheimer disease.